Prenetics Global Limited (NASDAQ:PRE - Get Free Report) was the recipient of a large increase in short interest during the month of May. As of May 31st, there was short interest totalling 34,500 shares, an increase of 46.2% from the May 15th total of 23,600 shares. Based on an average trading volume of 21,200 shares, the days-to-cover ratio is currently 1.6 days. Approximately 0.4% of the shares of the stock are short sold.
Prenetics Global Price Performance
PRE remained flat at $7.01 during midday trading on Monday. 81,930 shares of the company's stock traded hands, compared to its average volume of 19,125. Prenetics Global has a 52-week low of $3.09 and a 52-week high of $11.99. The company has a market capitalization of $85.56 million, a P/E ratio of -1.76 and a beta of 0.17. The firm has a fifty day moving average price of $6.32 and a 200-day moving average price of $5.53.
Prenetics Global (NASDAQ:PRE - Get Free Report) last issued its earnings results on Thursday, June 12th. The company reported ($0.80) EPS for the quarter. The business had revenue of $17.31 million for the quarter. Prenetics Global had a negative net margin of 191.73% and a negative return on equity of 16.45%. On average, research analysts anticipate that Prenetics Global will post -3.3 EPS for the current fiscal year.
Institutional Trading of Prenetics Global
A hedge fund recently bought a new stake in Prenetics Global stock. Quinn Opportunity Partners LLC acquired a new stake in Prenetics Global Limited (NASDAQ:PRE - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 12,339 shares of the company's stock, valued at approximately $72,000. Quinn Opportunity Partners LLC owned 0.10% of Prenetics Global as of its most recent filing with the SEC. 25.01% of the stock is currently owned by hedge funds and other institutional investors.
About Prenetics Global
(
Get Free Report)
Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Prenetics Global, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prenetics Global wasn't on the list.
While Prenetics Global currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
